512 results on '"Blau, Igor Wolfgang"'
Search Results
102. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
103. Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation
104. A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials
105. Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal
106. Characteristics of DNMT3A-R882 Mutation in AML
107. Genetic Risk of Severe Chronic Graft-Versus-Host Disease Defined By Host-Derived CXCR3 Ligands
108. Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT)
109. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors
110. Hope for Motherhood: Pregnancy After Allogeneic Hematopoietic Cell Transplantation – a National Multicenter Study
111. Single Nucleotide Polymorphisms in CD40L Predict Endothelial Complications and Mortality After Allogeneic Stem-Cell Transplantation
112. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma
113. A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma
114. European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including Second Primary Malignancies, in a Large Cohort of Patients (Pts) Treated With Lenalidomide (LEN), Thalidomide (THAL), and Bortezomib (BORT)
115. Efficacy of Adoptive Immunotherapy By Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation from Related an Unrelated Donors: A Single Center Retrospective Analysis
116. DNMT3A Mutations in AML Patients: Prognostic Impact and Comparative Analysis of Mutations Burden in Diagnostic Samples, after Standard Therapy, and after Allogeneic Stem Cell Transplantation
117. Evaluation of Stem Cell Mobilization in Patients with Multiple Myeloma after Lenalidomide-Based Induction Chemotherapy within the GMMG-HD6 Trial
118. Somatic Mutations in Myelodysplastic Syndrome Patients in the Context of Allogeneic Stem Cell Transplantation
119. Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy
120. Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial
121. Tyrosine Kinases in Cancer
122. Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial
123. Rabbit antithymocyte globulin induces rapid expansion of effector memory CD8 T cells without accelerating acute graft versus host disease
124. Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial
125. Prophylactic immunoglobulin therapy in secondary immune deficiency – an expert opinion
126. Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies
127. Quantitative Detection of DNMT3A R882H Mutation in Course of Treatment of Acute Myeloid Leukemia Patients
128. SIRT3 Modulates Mitochondrial Stress Response in Bone Marrow Mesenchymal Stromal Cells of Multiple Myeloma Patients
129. Multiple myeloma cells modify VEGF/IL‐6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR‐223
130. Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial
131. Direct Assessment of IgA and IgG Paraprotein By Hevylite Assay and Correlation to IMWG Response and Progression-Free Survival in Newly Diagnosed, Transplant-Eligible Multiple Myeloma Patients in the Prospective Phase III GMMG-MM5 Trial
132. Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial
133. Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)
134. Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia
135. Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region
136. Introductory Editorial: Tyrosine Kinases in Cancer
137. Multiple Myeloma Cells Induce Mitochondrial Stress Response in Bone Marrow Mesenchymal Stromal Cells
138. Cyclin D1 C.870G>a Polymorphism in Patients with Multiple Myeloma after Allogeneic Stem Cells Transplantation
139. Single-Nucleotide Polymorphisms Within the Thrombomodulin Gene (THBD) Predict Mortality in Patients With Graft-Versus-Host Disease
140. Lack of evidence that false-positive Aspergillus galactomannan antigen test results are due to treatment with piperacillin-tazobactam
141. Untersuchungen des hämatopoetischen Chimärismus nach der allogenen Stammzelltransplantation und Konditionierung mit reduzierter Intensität
142. Multiple myeloma cells modify VEGF/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR-223.
143. Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia
144. A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course
145. Efficacy and Pharmacologic Data of Second-Generation Tyrosine Kinase Inhibitor Nilotinib in BCR-ABL-Positive Leukemia Patients with Central Nervous System Relapse after Allogeneic Stem Cell Transplantation
146. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma
147. Treosulfan Based Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myelogenous Leukemia (AML): A Retrospective Analysis From The ALWP Of The EBMT
148. Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial
149. GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy
150. Long term efficacy of WT1 peptide vaccine in patients with WT1 overexpressing hematopoeitic and solid malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.